T. Rowe Price Associates
SRPT icon

T. Rowe Price Associates’s Sarepta Therapeutics SRPT Stock Holding History

T. Rowe Price Associates’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.25M Buy
103,287
+13,249
+15% +$256K ﹤0.01% 1778
2025
Q4 		$1.94M Buy
90,038
+11
+0% +$232 ﹤0.01% 1762
2025
Q3 		$1.74M Buy
90,027
+13,243
+17% +$236K ﹤0.01% 1794
2025
Q2 		$1.31M Sell
76,784
-161,464
-68% -$6.89M ﹤0.01% 1844
2025
Q1 		$15.2M Sell
238,248
-3,415
-1% -$359K ﹤0.01% 1021
2024
Q4 		$29.4M Buy
241,663
+5,130
+2% +$629K ﹤0.01% 898
2024
Q3 		$29.5M Sell
236,533
-103,497
-30% -$14.3M ﹤0.01% 897
2024
Q2 		$53.7M Sell
340,030
-164,938
-33% -$21.2M 0.01% 705
2024
Q1 		$65.4M Sell
504,968
-234,768
-32% -$28.8M 0.01% 650
2023
Q4 		$71.3M Sell
739,736
-48,220
-6% -$4.63M 0.01% 607
2023
Q3 		$95.5M Buy
787,956
+7,035
+0.9% +$795K 0.01% 522
2023
Q2 		$89.4M Sell
780,921
-390,521
-33% -$50.4M 0.01% 551
2023
Q1 		$161M Buy
1,171,442
+334,749
+40% +$43.4M 0.02% 417
2022
Q4 		$108M Sell
836,693
-382,178
-31% -$44.3M 0.02% 476
2022
Q3 		$135M Buy
1,218,871
+55,024
+5% +$5.55M 0.02% 435
2022
Q2 		$87.2M Buy
1,163,847
+27,042
+2% +$1.99M 0.01% 704
2022
Q1 		$88.8M Buy
1,136,805
+401,247
+55% +$30.7M 0.01% 766
2021
Q4 		$66.2M Buy
735,558
+26,114
+4% +$2.23M 0.01% 901
2021
Q3 		$65.6M Sell
709,444
-11,748
-2% -$905K 0.01% 915
2021
Q2 		$56.1M Buy
721,192
+17,039
+2% +$1.29M 0.01% 986
2021
Q1 		$52.5M Sell
704,153
-598,498
-46% -$55.2M 0.01% 985
2020
Q4 		$222M Sell
1,302,651
-38,402
-3% -$5.69M 0.02% 499
2020
Q3 		$188M Sell
1,341,053
-225,320
-14% -$34.2M 0.02% 497
2020
Q2 		$251M Sell
1,566,373
-120,426
-7% -$16.4M 0.03% 430
2020
Q1 		$165M Sell
1,686,799
-1,635,105
-49% -$187M 0.03% 457
2019
Q4 		$429M Sell
3,321,904
-466,165
-12% -$47.1M 0.06% 328
2019
Q3 		$285M Sell
3,788,069
-114,158
-3% -$13.5M 0.04% 377
2019
Q2 		$593M Buy
3,902,227
+359,160
+10% +$43.6M 0.08% 251
2019
Q1 		$422M Sell
3,543,067
-843,109
-19% -$108M 0.06% 295
2018
Q4 		$479M Buy
4,386,176
+311,176
+8% +$38.9M 0.08% 239
2018
Q3 		$658M Sell
4,075,000
-420,963
-9% -$57.5M 0.1% 218
2018
Q2 		$594M Buy
4,495,963
+1,097,796
+32% +$104M 0.09% 220
2018
Q1 		$252M Buy
3,398,167
+1,528,091
+82% +$102M 0.04% 404
2017
Q4 		$104M Buy
1,870,076
+1,087,295
+139% +$57.6M 0.02% 628
2017
Q3 		$35.5M Buy
782,781
+515,862
+193% +$20.6M 0.01% 985
2017
Q2 		$9M Sell
266,919
-93,754
-26% -$3.05M ﹤0.01% 1337
2017
Q1 		$10.7M Sell
360,673
-20,500
-5% -$634K ﹤0.01% 1320
2016
Q4 		$10.5M Sell
381,173
-153,295
-29% -$6.16M ﹤0.01% 1306
2016
Q3 		$32.8M Buy
534,468
+475,600
+808% +$14.4M 0.01% 948
2016
Q2 		$1.12M Buy
58,868
+6,100
+12% +$113K ﹤0.01% 1672
2016
Q1 		$1.03M Buy
52,768
+21,100
+67% +$369K ﹤0.01% 1696
2015
Q4 		$1.22M Buy
31,668
+120
+0.4% +$3.89K ﹤0.01% 1637
2015
Q3 		$1.01M Sell
31,548
-7,200
-19% -$244K ﹤0.01% 1701
2015
Q2 		$1.18M Buy
38,748
+12,200
+46% +$249K ﹤0.01% 1701
2015
Q1 		$353K Buy
26,548
+12,400
+88% +$165K ﹤0.01% 2120
2014
Q4 		$205K Hold
14,148
– – ﹤0.01% 2343
2014
Q3 		$299K Hold
14,148
– – ﹤0.01% 2151
2014
Q2 		$421K Buy
14,148
+2,500
+21% +$79K ﹤0.01% 2019
2014
Q1 		$280K Buy
+11,648
New +$297K ﹤0.01% 2189
2013
Q4 		– Sell
-17,048
Closed -$805K – 2511
2013
Q3 		$805K Sell
17,048
-857,200
-98% -$33M ﹤0.01% 1728
2013
Q2 		$33.3M Buy
+874,248
New +$31.3M 0.01% 922

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's SRPT Position: Q1 2026 in Review

T. Rowe Price Associates increased its Sarepta Therapeutics (SRPT) stake by 15% in Q1 2026, buying an estimated $256K and bringing the position to 103,287 shares worth $2.25M. The position accounts for ﹤0.01% of the portfolio, ranked #1778.

T. Rowe Price Associates first reported a position in SRPT in Q2 2013 and has held it in 51 quarters since. The position peaked at $658M in Q3 2018. 339 funds tracked by Wall St. Rank hold SRPT as of Q1 2026.

  • T. Rowe Price Associates held 103,287 shares of Sarepta Therapeutics worth $2.25M as of Q1 2026.
  • T. Rowe Price Associates bought 13,249 Sarepta Therapeutics shares in Q1 2026, an estimated $256K.
  • Sarepta Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1778 holding.
  • T. Rowe Price Associates first reported a position in Sarepta Therapeutics in Q2 2013 and has held it in 51 quarters since.
  • T. Rowe Price Associates's Sarepta Therapeutics position peaked at $658M in Q3 2018.
  • 339 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.